LoadingLoadingLoadingNet selling: insiders sold $15M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (3)
Two Sigma
$188.0M
added
Two Sigma
$35.5M
added
JPMorgan Chase
$42.4M
added
No tracked top-trader positions in INCY as of Oct 21, 19:23 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Jul 28, 2026
Financial period
Q2 2026
Earnings per share
$2.15 expected
Revenue
Company release
FY2026 guidance
$5.13B to $5.26B
No comparable estimate
Estimates as of Oct 21, 2026
EPS expected
-$4.46 to -$2.85
Revenue expected
20 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 28, 2026 | $3.09 / $2.15Yahoo Finance | +43.95% beat | $1.67B No estimate | Unavailable |
| Mar 31, 2026 | Apr 28, 2026 | $1.81 / $1.34Yahoo Finance | +35.12% beat | $1.27B No estimate | Unavailable |
| Dec 31, 2025 | Feb 10, 2026 | $1.80 / $1.92Yahoo Finance | -6.08% miss | $1.51B No estimate | Unavailable |
| Sep 30, 2025 | Oct 28, 2025 | $2.26 / $1.64Yahoo Finance | +38.04% beat | $1.37B No estimate | Unavailable |
| Jun 30, 2025 | Jul 29, 2025 | $1.57 / $1.47Alpha Vantage | +6.80% beat | $1.22B No estimate | Unavailable |
| Mar 31, 2025 | Apr 29, 2025 | $1.16 / $1.03Alpha Vantage | +12.62% beat | $1.05B No estimate | Unavailable |
| Dec 31, 2024 | Feb 10, 2025 | $1.43 / $1.55Alpha Vantage | -7.74% miss | $1.18B No estimate | Unavailable |
| Sep 30, 2024 | Oct 29, 2024 | Unavailable | - | $1.14B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.37B | $1.51B | $1.27B | $1.67B |
| Cost of what it sold | $99.0M | $121.1M | $104.5M | $105.0M |
| Gross profit | $1.27B | $1.39B | $1.17B | $1.57B |
| What it spent | ||||
| Research and development | $506.6M | $611.4M | $515.9M | $517.0M |
| Sales and admin | $329.1M | $390.4M | $328.1M | $351.7M |
| Total operating expenses | $835.7M | $1.00B | $844.0M | $871.2M |
| What was left | ||||
| Operating profit | $431.3M | $384.0M | $324.2M | $697.9M |
| Interest on debt | $592.0K | $582.0K | $569.0K | $581.0K |
| Profit before tax | $482.3M | $389.9M | $343.6M | $751.5M |
| Tax | $58.1M | $90.7M | $40.3M | $165.9M |
| Net profit | $424.2M | $299.3M | $303.3M | $585.6M |
| EBITDA | $506.9M | $414.5M | $368.0M | $778.6M |
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Morgan Stanley initiates Incyte stock coverage with Equalweight rating By Investing.com
Leans bullishOct 20Form 4 Incyte Corporation: Pablo J. Cagnoni (President, Global Head of R&D) For: 15 October
NeutralOct 20Form 4 Incyte Corporation: Pablo J. Cagnoni (President, Global Head of R&D) For: 15 October
NeutralOct 20Incyte president Cagnoni sells $297,779 in common stock By Investing.com
NeutralOct 20Incyte president Cagnoni sells $297,779 in common stock By Investing.com
Leans bullishOct 20Form 4 Incyte Corporation: Pablo J. Cagnoni (President, Global Head of R&D) For: 15 October
NeutralOct 20An Incyte (INCY) officer exercises options and sells 2,642 shares at $112.71.
Leans bearishOct 19Pfizer (PFE) Gets a Hold from Wells Fargo
NeutralOct 19
